Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Michigan
With
Otsuka Pharmaceuticals
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥ 18 years old
Prior clinical diagnosis of systolic heart failure (EF \< 40% within the past 18 months) with daily home use of oral loop diuretic for at least one month.
Daily oral dose of furosemide ≥ 40 mg and ≤ 240 mg (or equivalent)
Identified within 24 hours of hospital admission
Heart failure defined by at least 1 symptom (dyspnea, orthopnea, or edema) AND 1 sign (rales on auscultation, peripheral edema, ascites, pulmonary vascular congestion on chest radiography)
Anticipated need for IV loop diuretics for at least 48 hours
Likely requires daily net urine output in the range of 1-3 L/day for over a 72-96 hour time period.
Albumin level \< 3.5 g/dL
Willingness to provide informed consent
You may not be if
Received or planned IV vasoactive treatment (inotropes, vasodilators) or ultra-filtration therapy for heart failure
BNP \< 250 ng/ml or NT-proBNP \< 1000 mg/ml (if drawn for clinical purposes)
Systolic BP \< 90 mmHg
Serum creatinine \> 3.0 mg/dl at baseline or renal replacement therapy or creatinine clearances \< 10 mL/min
Serum sodium \> 145 mEq/L
Acute coronary syndrome within 4 weeks
Anticipated need for coronary angiography or other procedures requiring IV contrast.
Patients receiving any of the following drugs: clarithromycin, ketoconazole, itraconazole,ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, telithromycin, erythromycin, fluconazole, aprepitant, diltiazem, verapamil, cyclosporine, and grapefruit juice.
